Anthera Pharmaceuticals Inc (NASDAQ:ANTH) fell 8.8% during trading on Friday . The stock traded as low as $1.32 and last traded at $1.35. 1,540,554 shares traded hands during trading, an increase of 179% from the average session volume of 551,595 shares. The stock had previously closed at $1.48.
Several brokerages recently commented on ANTH. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. Finally, Zacks Investment Research downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.32. During the same period in the previous year, the company earned ($4.85) EPS. analysts forecast that Anthera Pharmaceuticals Inc will post -3.09 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first published by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://baseballnewssource.com/markets/anthera-pharmaceuticals-anth-shares-down-8-8/1831156.html.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.